High efficiency diffusion molecular retention tumor targeting.

High efficiency diffusion molecular retention tumor targeting.
复制标题

DOI:
10.1371/journal.pone.0058290
复制
发表时间:
2013
期刊:
影响因子:
3.7
通讯作者:
Josephson L
Josephson L
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Guo Y;Yuan H;Cho H;Kuruppu D;Jokivarsi K;Agarwal A;Shah K;Josephson L

文献摘要

参考文献

被引文献

相似文献

在这里,我们介绍扩散分子保留 (DMR) 肿瘤靶向技术,该技术采用 PEG 荧光染料屏蔽探针,在瘤周 (PT) 注射后,经历缓慢的血管摄取和广泛的间质扩散,仅通过整合素分子识别来保留肿瘤。为了证明 DMR,合成了带有 DOTA(111 In3+)、NIR 荧光染料和 5 kDa PEG 的 RGD(整联蛋白结合)和 RAD(对照)探针,赋予探针 25 kDa 的类蛋白质体积并减少非特异性相互作用。使用 GFP-BT-20 乳腺癌模型,通过表面荧光、[111In]RGD 和 [111In]RAD 探针的生物分布以及整个动物 SPECT 评估 DMR 或 IV 方法的肿瘤靶向。注射 PT 后,两种探针迅速扩散通过正常和肿瘤间质,由于整合素相互作用,RGD 探针被保留。通过 PT 注射和 [111In]RGD 探针,SPECT 显示注射后 24 小时具有高度肿瘤特异性摄取,通过 DMR 获得 352%ID/g 肿瘤(对比通过 IV 获得的 4.14%ID/g)。 DMR 的高效分子靶向采用低探针剂量(例如 RGD 肽 25 ng),从而最大限度地降低毒性风险并促进临床转化。 DMR 应用包括用于术中肿瘤边缘描绘的荧光染料的输送、用于放射治疗的放射性同位素(例如有毒的短程 α 发射体)的输送,或向可接触到光的肿瘤输送光敏剂。
Here we introduce diffusion molecular retention (DMR) tumor targeting, a technique that employs PEG-fluorochrome shielded probes that, after a peritumoral (PT) injection, undergo slow vascular uptake and extensive interstitial diffusion, with tumor retention only through integrin molecular recognition. To demonstrate DMR, RGD (integrin binding) and RAD (control) probes were synthesized bearing DOTA (for 111 In3+), a NIR fluorochrome, and 5 kDa PEG that endows probes with a protein-like volume of 25 kDa and decreases non-specific interactions. With a GFP-BT-20 breast carcinoma model, tumor targeting by the DMR or IV methods was assessed by surface fluorescence, biodistribution of [111In] RGD and [111In] RAD probes, and whole animal SPECT. After a PT injection, both probes rapidly diffused through the normal and tumor interstitium, with retention of the RGD probe due to integrin interactions. With PT injection and the [111In] RGD probe, SPECT indicated a highly tumor specific uptake at 24 h post injection, with 352%ID/g tumor obtained by DMR (vs 4.14%ID/g by IV). The high efficiency molecular targeting of DMR employed low probe doses (e.g. 25 ng as RGD peptide), which minimizes toxicity risks and facilitates clinical translation. DMR applications include the delivery of fluorochromes for intraoperative tumor margin delineation, the delivery of radioisotopes (e.g. toxic, short range alpha emitters) for radiotherapy, or the delivery of photosensitizers to tumors accessible to light.
DOI: 10.7150/thno.3582
发表时间: 2012
期刊: Theranostics
影响因子: 12.4
作者:
Goldenberg DM;Chang CH;Rossi EA;J W;McBride;Sharkey RM
通讯作者: Sharkey RM
DOI: 10.1042/bst0180750
发表时间: 1990-10-01
影响因子: 3.9
作者:
BAGSHAWE, KD
通讯作者: BAGSHAWE, KD
DOI: 10.1007/978-1-60761-901-7_13
发表时间: 2011-01-01
期刊: MOLEUCLAR IMAGING: METHODS AND PROTOCOLS
影响因子: --
作者:
Beer, Ambros J.;Schwaiger, Markus
通讯作者: Schwaiger, Markus
DOI: 10.1021/ja309085b
发表时间: 2012-11-28
影响因子: 15
作者:
Guo, Yanyan;Yuan, Hushan;Rice, William L.;Kumar, Anand T. N.;Goergen, Craig J.;Jokivarsi, Kimmo;Josephson, Lee
通讯作者: Josephson, Lee
DOI: 10.1021/bc015561
发表时间: 2002-01-01
影响因子: 4.7
作者:
Kok, RJ;Schraa, AJ;Molema, G
通讯作者: Molema, G